Fintel reports that on January 10, 2025, BMO Capital upgraded their outlook for Precision BioSciences (NasdaqCM:DTIL) from ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...

BMO Capital analyst Kostas Biliouris upgraded the rating on Precision BioSciences (DTIL – Research Report) to a Buy today, setting a price ...

Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...

Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...

Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/ ...

Pillar Biosciences, Inc. has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer ...

CFO John Alexander Kelly purchased 2,113 shares of Precision BioSciences stock in a transaction dated Friday, December 27th.

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...